AAP
RLAY icon

Arax Advisory Partners’s Relay Therapeutics RLAY Stock Holding History

Arax Advisory Partners’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$248K Buy
13,256
+13,029
+5,740% +$189K ﹤0.01% 2099
2026
Q1 		$2.26K Buy
227
+208
+1,095% +$1.86K ﹤0.01% 3076
2025
Q4 		$161 Sell
19
-15,038
-100% -$107K ﹤0.01% 3756
2025
Q3 		$78.6K Buy
+15,057
New +$57.4K ﹤0.01% 1630
2024
Q4 		– Sell
-372
Closed -$2.63K – 2691
2024
Q3 		$2.63K Sell
372
-666
-64% -$4.98K ﹤0.01% 1957
2024
Q2 		$6.77K Buy
+1,038
New +$7.09K ﹤0.01% 1451

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Arax Advisory Partners's RLAY Position: Q2 2026 in Review

Arax Advisory Partners increased its Relay Therapeutics (RLAY) stake by 5,740% in Q2 2026, buying an estimated $189K and bringing the position to 13,256 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #2099.

Arax Advisory Partners first reported a position in RLAY in Q2 2024 and has held it in 6 quarters since. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Arax Advisory Partners held 13,256 shares of Relay Therapeutics worth $248K as of Q2 2026.
  • Arax Advisory Partners bought 13,029 Relay Therapeutics shares in Q2 2026, an estimated $189K.
  • Relay Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2099 holding.
  • Arax Advisory Partners first reported a position in Relay Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.